At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 164 enrolled
Drug / intervention
TAK-063 20 mg +1 moredrug
Likely dose
TAK-063 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia
In Brief
A Phase 2 clinical trial evaluating TAK-063 20 mg and Placebo for Schizophrenia. Completed, enrolled 164 participants across 15 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophrenia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartJul 2015
Primary CompletionJul 2016
Study CompletionJul 2016
TodayJul 2026
First PostedJun 22, 2015
Enrollment StartJul 1, 2015
Primary CompletionJul 13, 2016
Study CompletionJul 27, 2016
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 11.0 years ago
Interventions
TAK-063 20 mgdrug
TAK-063 tablet.
Placebodrug
TAK-063 matching-placebo tablet.